Review Article

Effector and Regulatory T Cell Trafficking in Corneal Allograft Rejection

Afsaneh Amouzegar1,2 and Sunil K. Chauhan1,2

1Schepens Eye Research Institute, Massachusetts Eye and Ear Infirmary, Boston, MA, USA
2Department of Ophthalmology, Harvard Medical School, Boston, MA, USA

Correspondence should be addressed to Sunil K. Chauhan; sunil_chauhan@meei.harvard.edu

Received 24 January 2017; Accepted 26 March 2017; Published 28 April 2017

Academic Editor: Paul Proost

Copyright © 2017 Afsaneh Amouzegar and Sunil K. Chauhan. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Corneal transplantation is among the most prevalent and successful forms of solid tissue transplantation in humans. Failure of corneal allograft is mainly due to immune-mediated destruction of the graft, a complex and highly coordinated process that involves elaborate interactions between cells of innate and adaptive immunity. The migration of immune cells to regional lymphoid tissues and to the site of graft plays a central role in the immunopathogenesis of graft rejection. Intricate interactions between adhesion molecules and their counter receptors on immune cells in conjunction with tissue-specific chemokines guide the trafficking of these cells to the draining lymph nodes and ultimately to the site of graft. In this review, we discuss the cascade of chemokines and adhesion molecules that mediate the trafficking of effector and regulatory T cells during corneal allograft rejection.

1. Introduction

Corneal transplantation is one of the most successful forms of human solid organ transplantation. With more than 400,000 surgeries performed annually in the US and 100,000 worldwide, corneal transplantation is among the most widely performed transplant procedures in the world [1]. Despite the relatively high-acceptance rates of corneal allografts compared to other tissues, the fate of the corneal graft is highly dependent on the graft bed microenvironment. While the survival rates in normal recipients are approximately 90%, conditions such as host bed inflammation and vascularization or history of previous rejection, which render the host as high-risk, predispose graft recipients to high-failure rates around 50% [2–4].

The development of new surgical techniques and immunosuppressive drugs has considerably increased the success rate of corneal transplants. However, immune-mediated rejection remains the most common cause of graft failure. Although the cornea is an immune-privileged tissue, factors such as inflammation and neovascularization can disrupt this privilege and lead to the development of a graft-directed immune response [5]. The orchestrated response of innate and adaptive immune cells against the alloantigen is highly dependent on directed migration and homing of immune cells to the lymphoid tissues and site of inflammation [6]. This immune cell trafficking is regulated by a complex interplay between adhesion molecules and chemokines and their counter receptors. In this review, we focus on the migration and homing of the two most critical T cell subsets that are involved in graft alloimmunity, effector T cells and regulatory T cells, with an emphasis on the chemokines and adhesion molecules involved in the migration of these cells to the draining lymphoid tissues and the graft site.

2. Pathophysiology of Corneal Graft Rejection

Corneal allograft rejection is a multifaceted process that involves complex interactions between cells of innate and adaptive immunity. Response to allogeneic tissue begins following transplantation with upregulation of proinflammatory cytokines, adhesion molecules, and chemokines, which result in mobilization of antigen-presenting cells (APCs) from the vascular compartment and peripheral cornea to
the central cornea [7]. These mobilized APCs undergo a maturation process during which they acquire MHC class II and costimulatory molecules such as CD80 and CD86; a phenotypic change that makes them more potent in presenting the alloantigen to T cells [8, 9]. Furthermore, the resultant inflammatory milieu nullifies the effect of antigenic factors, such as PEDF, TSP-1, endostatin, and soluble VEGFR-3, that normally maintain the cornea in an avascular state [10]. This leads to the formation of neovessels and neolymphatics, which further facilitate the trafficking of mature APCs to the cornea and to draining lymph nodes, where priming of naïve T cells or allosensitization occurs [8].

Both donor and recipient-derived APCs have the capacity to present alloantigen-MHC complexes to naïve T (Th0) cells. T cell stimulation through donor APCs or passenger leukocytes is known as the direct pathway of allogrecognition, whereas the indirect pathway involves presentation of processed alloantigens to T cells through host APCs [11]. After activation, primed T cells undergo clonal expansion and give rise to CD4+ IFNγ+ T helper (Th1). Th1 cells are considered the main mediators of graft rejection and are the predominant cell population identified in the corneal stromal infiltrate of the grafts undergoing rejection [12, 13]. These effector CD4+ Th1 cells employ an array of mechanisms including the production of IL-2, IFNγ, and TNF-α cytokines, and FasL-mediated apoptosis of corneal endothelial cells to mount the delayed type hypersensitivity (DTH) immune response that results in the destruction of allogeneic corneal tissue [4, 11, 14, 15]. CD40Foxp3+ regulatory T (Treg) cells, on the other hand, can interact with and regulate the function of both APCs and T cells and are a pivotal part of inducing immunologic tolerance against the graft [16]. The fate of the corneal allograft is highly dependent on the balance between the effector T cell and regulatory T cell responses, each deviating the immune response towards either rejection or tolerance.

3. Trafficking and Homing of Effector T Cells

3.1. Homing of Naïve T Cells to the Draining Lymph Nodes. Directed migration of T cells to the site of graft depends on a complex cascade of adhesion molecules, integrins, and chemokines. Circulating naïve T cells migrate to the parenchyma of draining lymph nodes through specialized postcapillary venules called high endothelial venules (HEVs) (Figure 1). Rolling of T cells in HEVs is mediated through the interaction of T cell-expressed L-selectin (CD62L) with peripheral node addressin (PNAd) expressed by HEVs [17]. Transendothelial migration of T cells to peripheral lymphoid tissues begins with firm attachment of T cells to HEVs through binding of CC-chemokine receptor 7 (CCR7) expressed on T cells with its ligands, CC-chemokine ligand 19 (CCL19) and CCL21, which are present on HEVs [18]. CCR7 is a critical homing molecule for migration of both T cells and antigen-presenting cells to the secondary lymphoid tissues [18, 19]. The binding of CCR7 with CCL21 results in activation of the integrin lymphocyte function-associated antigen-1 (LFA-1), which mediates the arrest and transendothelial migration of T cells to the paracortical or T cell zones of the secondary lymph nodes through interactions with intercellular adhesion molecule-1 (ICAM-1) [20]. ICAM-1 is constitutively expressed on endothelial cells of limbal vessels and keratocytes in the cornea [21]. In corneal allografts undergoing rejection, the expression of ICAM-1 is increased on vascular endothelial cells and keratocytes, especially at the site of T cell infiltration [21]. Increased expression of ICAM-1 associated with increased leukocyte infiltration has also been demonstrated in a murine model of suture-induced corneal inflammation [22]. Once transmigrated to T cell zone of the lymphoid tissues, the mobility of T cells depends on the interactions of CCR7 with CCL19 and CCL21 ligands. T cell motility within the lymphoid tissue enhances T cell scanning of antigen-presenting cells and increases the possibility of T cell priming [23].

3.2. Egress of Effector T Cells from the Draining Lymph Nodes. The migration of primed T cells out of the lymph nodes rests on the sphingosine-1 phosphate (SIP) chemoattractant gradient and the expression levels of SIP receptor on T cells [24, 25]. SIP levels are significantly higher in blood vessels and lymphatics than in T cell zones of the secondary lymph nodes. This chemoattractant gradient directs T cells out of lymph nodes and ensures their recirculation [25]. However, during inflammation, T cells must remain in the draining lymph nodes for a sufficient amount of time to encounter antigen-bearing APCs. Initial T cell receptor activation and production of proinflammatory cytokines such as IFNγ result in upregulation of CD69 by T cells [17]. CD69 has been shown to internalize the SIP receptor and prevent its surface expression on T cells; thereby desensitizing T cells to SIP gradient [24, 26, 27]. This results in retention of T cells in the secondary lymph nodes and increases their chances of encountering a mature antigen-bearing APC. Treatment with SIP type I receptor agonist has been shown to inhibit migration of lymphocytes and promote the survival of corneal allografts [28, 29]. After activation, T cell expression of SIP receptor increases, while the expression of lymphoid homing molecules L-selectin (CD62L) and CCR7 decreases substantially [30, 31]. These phenotypic changes lead to the migration of primed effector T cells out of the draining lymph nodes in response to the SIP gradient and prevent them from re-entering the lymphoid tissue (Figure 1).

3.3. Migration of Effector T Cells to the Site of Graft. Several chemokines have been implicated in the recruitment of antigen-primed effector T cells towards the inflamed cornea (Figure 1). Overexpression of CCL2, CCL3, CCL4, CXCL10/IP-10, and CCL5/RANTES chemokines has been detected in corneal allografts undergoing rejection [32]. Early production of CXCL1 in high-risk graft recipients upregulates the expression of T cell-specific chemokines, CXCL9 and CXCL10/IP-10, which recruit alloantigen-specific T cells to the site of graft [33]. Blockade of CXCL1 has been associated with decreased expression of CXCL9 and CXCL10, less graft infiltration of CD4+ T cells, and has been shown to significantly improve the survival of vascularized high-risk corneal allografts [33]. In addition to higher levels of
selective chemokines, corneal graft rejection is also associated with upregulated expression of chemokine receptors CCR1, CCR2, and CCR5 [34]. CCR1 knockout corneal graft recipients demonstrate reduced T cell graft infiltration, suppressed expression of Th1-associated cytokines, and significantly improved corneal allograft survival [34].
Once migrated out of the lymphoid tissue towards the graft, effector T cells extravasate from the blood vessels to the graft tissue. Transmigration of T cells within blood vessels is mediated by selectins and integrins. Vascular endothelial cells express E- (endothelial-) and P- (platelet-) selectins [35]. Interactions of these selectins with their ligands, PSGL-1 and glycosylated CD43, which are expressed on circulating effector cells, initiate the transendothelial migration of effector Th1 cells [35, 36]. Selectins have been detected on the endothelium of vasculature in rejected corneal allografts [21]. It has been shown that the expression of both P-selectin and E-selectin by CD31+ vascular endothelial cells gets upregulated in rejected corneal allografts [37]. Both P- and E-selectins have been shown to mediate the recruitment of Th1 cells, but not Th2 cells in inflamed tissues [36]. Anti-E- and anti-P-selectin treatment decreases corneal infiltration of CD4+ T cells in transplanted mice, and E-selectin blockade significantly improves corneal allograft survival [37]. Firm attachment of effector T cells to vascular endothelial cells is mediated through interactions of T cell–expressed integrins, LFA-1 and very late antigen–4 (VLA-4) with ICAM-1 and VCAM-1, respectively. High expressions of ICAM-1 and its counter receptor LFA-1 have been detected in corneal allografts undergoing rejection [38]. Treatment of mice undergoing corneal transplantation with systemic anti-LFA-1 and anti-VLA-4 monoclonal antibodies significantly reduces effector Th1 responses and promotes corneal allograft survival [39, 40]. The expression of very late antigen-1 (VLA-1) integrin has also been demonstrated in grafted corneas [41]. VLA-1 is normally expressed on CD4+ T cells, and its expression is upregulated upon T cell activation [42]. Blockade of VLA-1 in a murine model of corneal transplantation has been shown to dramatically decrease infiltration of inflammatory cells, including T cells, and improve corneal allograft survival [41]. Interestingly, emerging data has shown that corneal allograft rejection is not only dependent on frequencies of infiltrating T cells but is also associated with a distinct phenotype of T cells that are highly mobile within the allograft stroma [43]. CCR5/CXCR3 signaling plays a significant role in the motility patterns of infiltrating T cells. Blockade of CCR5/CXCR3 pathway alters the phenotype of graft-infiltrating T cells to that of less mobile cells and significantly promotes corneal allograft survival [43].

4. Trafficking and Homing of Regulatory T Cells

Tregs modulate the immune response to the allograft by inducing and maintaining tolerance to alloantigens [44]. Tregs exert their regulatory function in two primary locations: the draining lymph nodes and the inflamed tissue [45, 46]. Tregs have been demonstrated to regulate the alloimmune response to corneal allograft primarily by suppressing T cell priming in the draining lymph nodes, rather than by controlling effector T cell responses in the inflamed cornea [47]. In addition, despite the increase in absolute frequencies of Tregs in the corneas undergoing rejection, the suppressive activity of graft-infiltrating Tregs is not significantly different between graft acceptors and rejectors. Lymph node-derived Tregs from graft acceptors, however, demonstrate significantly higher capacity in suppressing T cell activation [47, 48]. This highlights the significance of proper localization of Tregs to draining lymph nodes in the regulation of graft-directed immune response.

The majority of Tregs derived from draining lymph nodes of corneal allograft recipients express CCR7 and CD62L (Figure 1), and to a much lesser extent CD103 [48]. CCR7 and L-selectin (CD62L) homing receptors mediate the migration of Tregs from the thymus to the paracortical regions of draining lymph nodes through HEVs, where they make contact with antigen-presenting cells [49, 50]. CD103, on the other hand, has been implicated in retention of Tregs in inflamed tissues [51]. CCR7 appears to have a paradoxical function; it facilitates allosensitization by promoting the migration of antigen-presenting cells to draining lymph nodes, but at the same time, it enhances lymph node homing and suppressive function of Tregs [52, 53]. Data has shown that Tregs derived from draining lymph nodes of corneal allograft acceptors express higher levels of CCR7 compared to those of graft rejectors [48]. Ex vivo augmentation of CCR7 expression by naïve Tregs through CCL21 stimulation promotes Treg homing to draining lymph nodes and enhances corneal allograft survival [48].

5. Conclusions

The migration of leukocytes to the site of inflammation is a complex and multistep process, which is indispensable to induction of optimal host immune response. This directed trafficking forms the basis of effector immune responses that ultimately lead to destruction of the allograft tissue. The intricate interactions between chemokines and adhesion molecules and their counterpart receptors on immune cells have been intriguing research targets in various transplantation contexts. A better understanding of the key molecular players involved in organ-specific targeted migration of leukocytes, and their effector function at the site of graft could provide therapeutic opportunities to manipulate these interactions in favor of prolonging corneal allograft survival.

Conflicts of Interest

The authors declare no financial conflicts of interest.

Acknowledgments

This work was supported by National Institutes of Health Grant no. EY024602 to Sunil K. Chauhan.

References

[1] M. Nagata, T. Nakamura, Y. Hata, S. Yamaguchi, T. Kaku, and S. Kinoshita, "JB485 promotes corneal epithelial wound healing," *Scientific Reports*, vol. 5, p. 14776, 2015.

[2] M. R. Dana, Y. Qian, and P. Hamrah, "Twenty-five-year panorama of corneal immunology: emerging concepts in the immunopathogenesis of microbial keratitis, peripheral ulcerative keratitis, and corneal transplant rejection," *Cornea*, vol. 19, no. 5, pp. 625–643, 2000.
[3] J. Y. Niederkorn and D. F. Larkin, “Immune privilege of corneal allografts,” *Ocular Immunology and Inflammation*, vol. 18, no. 3, pp. 162–171, 2010.

[4] J. Y. Niederkorn, “Immune mechanisms of corneal allograft rejection,” *Current Eye Research*, vol. 32, no. 12, pp. 1005–1016, 2007.

[5] J. Y. Niederkorn, “High-risk corneal allografts and why they lose their immune privilege,” *Current Opinion in Allergy and Clinical Immunology*, vol. 10, no. 5, pp. 493–497, 2010.

[6] E. Ingulli, “Mechanism of cellular rejection in transplantation,” *PEDIATRIC nephrology*, vol. 25, no. 1, pp. 61–74, 2010.

[7] A. Amouzegar, S. K. Chauhan, and R. Dana, “Alloimmunity and tolerance in corneal transplantation,” *Journal of Immunology*, vol. 196, no. 10, pp. 3983–3991, 2016.

[8] E. M. Chong and M. R. Dana, “Graft failure IV. Immunologic mechanisms of corneal transplant rejection,” *International Ophthalmology*, vol. 28, no. 3, pp. 209–222, 2008.

[9] P. Hamrah, Y. Liu, Q. Zhang, and M. R. Dana, “Alterations in corneal stromal dendritic cell phenotype and distribution in inflammation,” *Archives of Ophthalmology*, vol. 121, no. 8, pp. 1132–1140, 2003.

[10] D. Ellenberg, D. T. Azar, J. A. Hallak et al., “Novel aspects of corneal angiogenic and lymphangiogenic privilege,” *Progress in Retinal and Eye Research*, vol. 29, no. 3, pp. 208–248, 2010.

[11] S. Huq, Y. Liu, G. Benichou, and M. R. Dana, “Relevance of the direct pathway of sensitization in corneal transplantation is dictated by the graft bed microenvironment,” *Journal of Immunology*, vol. 173, no. 7, pp. 4646–4669, 2004.

[12] D. F. Larkin, R. A. Alexander, and I. A. Cree, “Infiltrating inflammatory cell phenotypes and apoptosis in rejected human corneal allografts,” *Eye (London, England)*, vol. 11, Part 1, pp. 68–74, 1997.

[13] J. Yamada, I. Kurimoto, and J. W. Streilein, “Role of CD4+ T cells in immunobiology of orthotopic corneal transplants in mice,” *Investigative Ophthalmology & Visual Science*, vol. 40, no. 11, pp. 2614–2621, 1999.

[14] F. Boisgerault, Y. Liu, N. Anosova, E. Ehrlich, M. R. Dana, and G. Benichou, “Role of CD4+ and CD8+ T cells in aller-recognition: lessons from corneal transplantation,” *Journal of Immunology*, vol. 167, no. 4, pp. 1891–1899, 2001.

[15] C. K. Joo, J. S. Pepose, and P. M. Stuart, “T-cell mediated responses in a murine model of orthotopic corneal transplantation,” *Investigative Ophthalmology & Visual Science*, vol. 36, no. 8, pp. 1530–1540, 1995.

[16] Q. Tang and J. A. Bluestone, “The Foxp3+ regulatory T cell: a jack of all trades, master of regulation,” *Nature Immunology*, vol. 9, no. 3, pp. 239–244, 2008.

[17] D. Masopust and J. M. Schenkel, “The integration of T cell migration, differentiation and function,” *Nature Reviews. Immunology*, vol. 13, no. 5, pp. 309–320, 2013.

[18] R. Forster, A. C. Davalos-Misslitz, and A. Rot, “CCR7 and its ligands: balancing immunity and tolerance,” *Nature Reviews. Immunology*, vol. 8, no. 5, pp. 362–371, 2008.

[19] R. Forster, A. Schubel, D. Breitfeld et al., “CCR7 coordinates the primary immune response by establishing functional microenvironments in secondary lymphoid organs,” *Cell*, vol. 99, no. 1, pp. 23–33, 1999.

[20] N. Hogg, A. Smith, A. McDowall et al., “How T cells use LFA-1 to attach and migrate,” *Immunology Letters*, vol. 92, no. 1-2, pp. 51–54, 2004.

[21] W. Philipp, “Leukocyte adhesion molecules in rejected corneal allografts,” *Graefe’s Archive for Clinical and Experimental Ophthalmology*, vol. 232, no. 2, pp. 87–95, 1994.

[22] S. N. Zhu and M. R. Dana, “Expression of cell adhesion molecules on limbal and neovascular endothelium in corneal inflammatory neovascularization,” *Investigative Ophthalmology & Visual Science*, vol. 40, no. 7, pp. 1427–1434, 1999.

[23] A. Kaiser, E. Donnadieu, J. P. Abastado, A. Trautmann, and A. Nardin, “CC chemokine ligand 19 secreted by mature dendritic cells increases naive T cell scanning behavior and their response to rare cognate antigen,” *Journal of Immunology*, vol. 175, no. 4, pp. 2349–2356, 2005.

[24] A. Baeyens, V. Fang, C. Chen, and S. R. Schwab, “Exit strategies: S1P signaling and T cell migration,” *Trends in Immunology*, vol. 36, no. 12, pp. 778–787, 2015.

[25] M. Matloubian, C. G. Lo, G. Cinnamon et al., “Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1,” *Nature*, vol. 427, no. 6972, pp. 355–360, 2004.

[26] A. J. Bankovich, L. R. Shiow, and J. G. Cyster, “CD69 suppresses sphingosine 1-phosphate receptor-1 (SIP1) function through interaction with membrane helix 4,” *The Journal of Biological Chemistry*, vol. 285, no. 29, pp. 22328–22337, 2010.

[27] L. R. Shiow, D. B. Rosen, N. Brdiczka et al., “CD69 acts downstream of interferon-alpha/beta to inhibit SIP1 and lymphocyte egress from lymphoid organs,” *Nature*, vol. 440, no. 7083, pp. 540–544, 2006.

[28] J. Zhu, Y. Liu, Y. Pi, L. Jia, L. Wang, and Y. Huang, “Systemic application of sphingosine 1-phosphate receptor 1 immunomodulator inhibits corneal allograft rejection in mice,” *Acta Ophthalmologica*, vol. 92, no. 1, pp. e12–e21, 2014.

[29] M. Gao, Y. Liu, Y. Xiao et al., “Prolonging survival of corneal transplantation by selective sphingosine-1-phosphate receptor 1 agonist,” *PloS One*, vol. 9, no. 9, article e105693, 2014.

[30] C. S. Garris, V. A. Blaho, T. Ha, and M. H. Han, “Sphingosine-1-phosphate receptor 1 signalling in T cells: trafficking and beyond,” *Immunology*, vol. 142, no. 3, pp. 347–353, 2014.

[31] O. Bjorkdahl, K. A. Barber, S. J. Brett et al., “Characterization of CC-chemokine receptor 7 expression on murine T cells in lymphoid tissues,” *Immunology*, vol. 110, no. 2, pp. 170–179, 2003.

[32] S. Yamagami, D. Miyazaki, S. J. Ono, and M. R. Dana, “Differential chemokine gene expression in corneal transplant rejection,” *Investigative Ophthalmology & Visual Science*, vol. 40, no. 12, pp. 2892–2897, 1999.

[33] G. Amescua, F. Collings, A. Sidani et al., “Effect of CXCL-1/KC production in high risk vascularized corneal allografts on T cell recruitment and graft rejection,” *Transplantation*, vol. 85, no. 4, pp. 615–625, 2008.

[34] P. Hamrah, S. Yamagami, Y. Liu et al., “Deletion of the chemokine receptor CCR1 prolongs corneal allograft survival,” *Investigative Ophthalmology & Visual Science*, vol. 48, no. 3, pp. 1228–1236, 2007.

[35] K. Ley and G. S. Kansas, “Selectins in T-cell recruitment to non-lymphoid tissues and sites of inflammation,” *Nature Reviews. Immunology*, vol. 4, no. 5, pp. 325–335, 2004.

[36] F. Austrup, D. Vestweber, E. Borges et al., “P- and E-selectin mediate recruitment of T-helper-1 but not T-helper-2 cells into inflamed tissues,” *Nature*, vol. 385, no. 6611, pp. 81–83, 1997.

[37] T. H. Dohlman, A. Di Zazzo, M. Omo et al., “E-selectin mediates immune cell trafficking in corneal transplantation,” *Transplantation*, vol. 100, no. 4, pp. 772–780, 2016.
[38] S. M. Whitcup, R. B. Nussenblatt, F. W. Price Jr, and C. C. Chan, "Expression of cell adhesion molecules in corneal graft failure," *Cornea*, vol. 12, no. 6, pp. 475–480, 1993.

[39] J. Hori, M. Isobe, S. Yamagami, T. Mizuochi, and T. Tsuru, "Specific immunosuppression of corneal allograft rejection by combination of anti-VLA-4 and anti-LFA-1 monoclonal antibodies in mice," *Experimental Eye Research*, vol. 65, no. 1, pp. 89–98, 1997.

[40] S. Yamagami, T. Tsuru, M. Isobe, H. Obata, and J. Suzuki, "The role of cell adhesion molecules in allograft rejection after penetrating keratoplasty in mice. Clinical and immunohistochemical study," *Graefes Archive for Clinical and Experimental Ophthalmology*, vol. 234, no. 6, pp. 382–387, 1996.

[41] L. Chen, S. Huq, H. Gardner, A. R. de Fougerolles, S. Barabino, and M. R. Dana, "Very late antigen (VLA)-1 blockade markedly promotes survival of corneal allografts," *Archives of Ophthalmology*, vol. 125, no. 6, pp. 783–788, 2007.

[42] I. Goldstein, S. Ben-Horin, J. Li, I. Bank, H. Jiang, and L. Chess, "Expression of the alphabeta1 integrin, VLA-1, marks a distinct subset of human CD4+ memory T cells," *The Journal of Clinical Investigation*, vol. 112, no. 9, pp. 1444–1454, 2003.

[43] Y. Tan, M. H. Abdulreda, F. Cruz-Guilloty et al., "Role of T cell recruitment and chemokine-regulated intra-graft T cell motility patterns in corneal allograft rejection," *American Journal of Transplantation*, vol. 13, no. 6, pp. 1461–1473, 2013.

[44] S. Sakaguchi, T. Yamaguchi, T. Nomura, and M. Ono, "Regulatory T cells and immune tolerance," *Cell*, vol. 133, no. 5, pp. 775–787, 2008.

[45] J. Huehn and A. Hamann, "Homing to suppress: address codes for Treg migration," *Trends in Immunology*, vol. 26, no. 12, pp. 632–636, 2005.

[46] P. T. Walsh, D. K. Taylor, and L. A. Turka, "Tregs and transplantation tolerance," *The Journal of Clinical Investigation*, vol. 114, no. 10, pp. 1398–1403, 2004.

[47] S. K. Chauhan, D. R. Saban, H. K. Lee, and R. Dana, "Levels of Foxp3 in regulatory T cells reflect their functional status in transplantation," *Journal of Immunology*, vol. 182, no. 1, pp. 148–153, 2009.

[48] S. K. Chauhan, D. R. Saban, T. H. Dohlman, and R. Dana, "CCL-21 conditioned regulatory T cells induce allotolerance through enhanced homing to lymphoid tissue," *Journal of Immunology*, vol. 192, no. 2, pp. 817–823, 2014.

[49] S. Ueha, H. Yoneyama, S. Hontsu et al., "CCR7 mediates the migration of Foxp3+ regulatory T cells to the paracortical areas of peripheral lymph nodes through high endothelial venules," *Journal of Leukocyte Biology*, vol. 82, no. 5, pp. 1230–1238, 2007.

[50] Z. Chow, A. Banerjee, and M. J. Hickey, "Controlling the fire—tissue-specific mechanisms of effector regulatory T-cell homing," *Immunology and Cell Biology*, vol. 93, no. 4, pp. 355–363, 2015.

[51] D. Chen and J. S. Bromberg, "T regulatory cells and migration," *American Journal of Transplantation*, vol. 6, no. 7, pp. 1518–1523, 2006.

[52] Y. Jin, S. K. Chauhan, D. R. Saban, and R. Dana, "Role of CCR7 in facilitating direct allosensitization and regulatory T-cell function in high-risk corneal transplantation," *Investigative Ophthalmology & Visual Science*, vol. 51, no. 2, pp. 816–821, 2010.

[53] Y. Jin, L. Shen, E. M. Chong et al., "The chemokine receptor CCR7 mediates corneal antigen-presenting cell trafficking," *Molecular Vision*, vol. 13, no. 9, pp. 626–634, 2007.